Literature DB >> 25042079

Targeted treatment of migrating partial seizures of infancy with quinidine.

David Bearden1, Alanna Strong, Jessica Ehnot, Marissa DiGiovine, Dennis Dlugos, Ethan M Goldberg.   

Abstract

Migrating partial seizures of infancy is an early onset epileptic encephalopathy syndrome that is typically resistant to treatment. The most common cause is a gain of function mutation in the potassium channel KCNT1. The antiarrhythmic drug quinidine is a partial antagonist of KCNT1 and hence may be a candidate drug for treatment of this condition. We report the case of a child with migrating partial seizures of infancy secondary to an activating mutation in KCNT1 treated with quinidine. Treatment with quinidine was correlated with a marked reduction in seizure frequency and improved psychomotor development.
© 2014 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25042079     DOI: 10.1002/ana.24229

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  53 in total

1.  Genetics of Epilepsy in Clinical Practice.

Authors:  Samuel F Berkovic
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

Review 2.  Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies.

Authors:  Ryan S Dhindsa; David B Goldstein
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 3.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

4.  Profile of neonatal epilepsies: Characteristics of a prospective US cohort.

Authors:  Renée A Shellhaas; Courtney J Wusthoff; Tammy N Tsuchida; Hannah C Glass; Catherine J Chu; Shavonne L Massey; Janet S Soul; Natrujee Wiwattanadittakun; Nicholas S Abend; Maria Roberta Cilio
Journal:  Neurology       Date:  2017-07-21       Impact factor: 9.910

5.  HCN1 Gain-Of-Function Mutations - A New Cause of Epileptic Encephalopathy.

Authors:  Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2014 Nov-Dec       Impact factor: 7.500

6.  Precision Medicine: NMDA Receptor-Targeted Therapy for GRIN2D Encephalopathy.

Authors:  Jennifer A Kearney
Journal:  Epilepsy Curr       Date:  2017 Mar-Apr       Impact factor: 7.500

7.  Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications.

Authors:  David S Auerbach; Yitschak Biton; Bronislava Polonsky; Scott McNitt; Robert A Gross; Robert T Dirksen; Arthur J Moss
Journal:  Transl Res       Date:  2017-10-20       Impact factor: 7.012

Review 8.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Treatment Responsiveness in KCNT1-Related Epilepsy.

Authors:  Mark P Fitzgerald; Martina Fiannacca; Douglas M Smith; Tracy S Gertler; Boudewijn Gunning; Steffen Syrbe; Nienke Verbeek; Hannah Stamberger; Sarah Weckhuysen; Berten Ceulemans; An-Sofie Schoonjans; Massimiliano Rossi; Geneviève Demarquay; Gaetan Lesca; Kern Olofsson; D A Koolen; Frauke Hornemann; Stephanie Baulac; Guido Rubboli; Kelly Q Minks; Bohoon Lee; Ingo Helbig; Dennis Dlugos; Rikke S Møller; David Bearden
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 10.  Stiripentol in the Management of Epilepsy.

Authors:  Katherine C Nickels; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.